kaleo

company

About

kaleo is a pharmaceutical company that develops combination drug products that empowers patients to control their medical conditions.

  • 251 - 500

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$15M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2005
Number Of Employee
251 - 500
Operating Status
Active

Intelliject is a specialty pharmaceutical company dedicated to developing combination drug/device products that empower patients to control and gain freedom from their medical conditions. Each Intelliject product in development combines an established drug, an innovative delivery platform and a supporting dossier intended to show superiority, patient preference and cost effectiveness data.

Intelliject applies rigorous selection criteria to identify areas where its patient-centric approach and proprietary technology will offer superior solutions. The company only proceeds to an active development program once it has established that incremental clinical and economic benefit is achievable. Intelliject has a focused pipeline of active programs across a number of therapeutic areas, including small molecules and biologics.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$15M
kaleo has raised a total of $15M in funding over 2 rounds. Their latest funding was raised on May 29, 2012 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 29, 2012 Debt Financing $15M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
kaleo is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Debt Financing